This meta-analysis and expert panel discussion evaluated the safety of topical estrogen (TE) therapy in breast cancer survivors undergoing adjuvant endocrine treatment with tamoxifen (TAM) or aromatase inhibitors (AIs). Analyzing six observational studies with 38,050 patients, including 1,805 exposed to TE, the study found that TE use with TAM did
